

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

<u>NEWS 1</u>		Web Page URLs for STN Seminar Schedule - N. America
<u>NEWS 2</u>		"Ask CAS" for self-help around the clock
<u>NEWS 3</u>	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
<u>NEWS 4</u>	FEB 28	BABS - Current-awareness alerts (SDIs) available
<u>NEWS 5</u>	MAR 02	GBFULL: New full-text patent database on STN
<u>NEWS 6</u>	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
<u>NEWS 7</u>	MAR 03	MEDLINE file segment of TOXCENTER reloaded
<u>NEWS 8</u>	MAR 22	KOREAPAT now updated monthly; patent information enhanced
<u>NEWS 9</u>	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
<u>NEWS 10</u>	MAR 22	PATDPASPC - New patent database available
<u>NEWS 11</u>	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
<u>NEWS 12</u>	APR 04	EPFULL enhanced with additional patent information and new fields
<u>NEWS 13</u>	APR 04	EMBASE - Database reloaded and enhanced
<u>NEWS 14</u>	APR 18	New CAS Information Use Policies available online
<u>NEWS 15</u>	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
<u>NEWS 16</u>	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
<u>NEWS 17</u>	MAY 23	GBFULL enhanced with patent drawing images
<u>NEWS 18</u>	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
<u>NEWS 19</u>	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
<u>NEWS 20</u>	JUN 13	RUSSIAPAT: New full-text patent database on STN
<u>NEWS 21</u>	JUN 13	FRFULL enhanced with patent drawing images
<u>NEWS 22</u>	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
<u>NEWS 23</u>	JUL 01	MEDICONF removed from STN
<u>NEWS 24</u>	JUL 07	STN Patent Forums to be held in July 2005
<u>NEWS 25</u>	JUL 13	SCISEARCH reloaded
<u>NEWS 26</u>	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
<u>NEWS EXPRESS</u>		JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
<u>NEWS HOURS</u>		STN Operating Hours Plus Help Desk Availability
<u>NEWS INTER</u>		General Internet Information
<u>NEWS LOGIN</u>		Welcome Banner and News Items
<u>NEWS PHONE</u>		Direct Dial and Telecommunication Network Access to STN
<u>NEWS WWW</u>		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:58:50 ON 10 AUG 2005

=> file uspatall

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'USPATFULL' ENTERED AT 18:59:06 ON 10 AUG 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:59:06 ON 10 AUG 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> e maclean d/in

E1	1	MACLEAN CRAIG I/IN
E2	2	MACLEAN CRAWFORD JAMIESON WILLIAM/IN
E3	0 -->	MACLEAN D/IN
E4	1	MACLEAN DANIEL S/IN
E5	5	MACLEAN DAVID/IN
E6	26	MACLEAN DAVID B/IN
E7	1	MACLEAN DAVID R/IN
E8	1	MACLEAN DAVID S/IN
E9	4	MACLEAN DEREK/IN
E10	42	MACLEAN DONALD L/IN
E11	1	MACLEAN DONALD R/IN
E12	3	MACLEAN DOUG/IN

=> s a6

L1 26 "MACLEAN DAVID B"/IN

=> d 1-26

L1 ANSWER 1 OF 26 USPATFULL on STN

Full  
Text

Claim  
References

AN 2005:171876 USPATFULL

TI Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions

IN MacLean, David B., Providence, RI, UNITED STATES  
Thompson, David D., Gales Ferry, CT, UNITED STATES

PA Pfizer Inc (U.S. corporation)

PI US 2005148625 A1 20050707

AI US 2005-71955 A1 20050303 (11)

RLI Division of Ser. No. US 2002-133006, filed on 26 Apr 2002, PENDING  
Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, GRANTED, Pat.  
No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb  
2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733,  
filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331

PRAI US 1996-13212P 19960228 (60)

DT Utility

FS APPLICATION

LN.CNT 1986

INCL INCLM: 514/310.000  
INCLS: 514/319.000; 514/343.000; 514/408.000

NCL NCLM: 514/310.000  
NCLS: 514/319.000; 514/343.000; 514/408.000

IC [7]  
ICM: A61K031-4709  
ICS: A61K031-454; A61K031-4439; A61K031-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:159258 USPATFULL  
 TI Use of growth hormone secretagogues for treatment of physical performance decline  
 IN MacLean, David B., Providence, RI, UNITED STATES  
 Landschulz, William H., East Lyme, CT, UNITED STATES  
 PA Pfizer Inc (U.S. corporation)  
 PI US 2004122062 A1 20040624  
 AI US 2003-720977 A1 20031124 (10)  
 RLI Continuation of Ser. No. US 2001-892702, filed on 27 Jun 2001, ABANDONED  
 PRAI US 2000-214980P 20000629 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1967  
 INCL INCLM: 514/355.000  
 INCLS: 514/423.000  
 NCL NCLM: 514/355.000  
 NCLS: 514/423.000  
 IC [7]  
 ICM: A61K031-44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:13471 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions  
 IN MacLean, David B., Providence, RI, UNITED STATES  
 Thompson, David D., Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc. (U.S. corporation)  
 PI US 2004009994 A1 20040115  
 AI US 2003-615282 A1 20030707 (10)  
 RLI Division of Ser. No. US 2001-999291, filed on 15 Nov 2001, GRANTED, Pat. No. US 6613796 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331  
 PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2058  
 INCL INCLM: 514/266.200  
 INCLS: 514/266.220; 514/256.000; 514/307.000; 514/314.000  
 NCL NCLM: 514/266.200  
 NCLS: 514/256.000; 514/266.220; 514/307.000; 514/314.000  
 IC [7]  
 ICM: A61K031-517  
 ICS: A61K031-506; A61K031-4709  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2003:312744 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions  
 IN MacLean, David B., Providence, RI, UNITED STATES

Thompson, David D., Gales Ferry, CT; UNITED STATES

PI US 2003220349 A1 20031127  
US 6911456 B2 20050628  
 AI US 2002-133006 A1 20020426 (10)  
 RLI Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, GRANTED, Pat. No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331  
 PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2038  
 INCL INCLM: 514/256.000  
 INCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000; 514/394.000; 514/415.000  
 NCL NCLM: 514/315.000  
 NCL NCLM: 514/256.000  
 NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000; 514/394.000; 514/415.000  
 IC [7]  
 ICM: A61K031-517  
 ICS: A61K031-506; A61K031-4709; A61K031-4184; A61K031-4439; A61K031-404  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:214288 USPATFULL  
 TI Therapy for andropause using estrogen agonists / antagonists and testosterone  
 IN **MacLean, David B.**, Providence, RI, UNITED STATES  
 PI US 2002115676 A1 20020822  
 AI US 2001-995130 A1 20011127 (9)  
 PRAI US 2000-250071P 20001130 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2692  
 INCL INCLM: 514/266.200  
 INCLS: 514/256.000; 514/314.000; 514/277.000  
 NCL NCLM: 514/266.200  
 NCLS: 514/256.000; 514/277.000; 514/314.000  
 IC [7]  
 ICM: A61K031-517  
 ICS: A61K031-505; A61K031-506  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:179201 USPATFULL  
 TI Intermittent administration of a growth hormone secretagogue  
 IN **MacLean, David B.**, Providence, RI, UNITED STATES  
 PI US 2002094992 A1 20020718  
 AI US 2001-940165 A1 20010827 (9)  
 PRAI US 2000-229077P 20000830 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2898  
 INCL INCLM: 514/303.000  
 NCL NCLM: 514/303.000

IC [7]  
 ICM: A61K031-4745  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 26 USPATFULL on STN

Full Text	Citing References
AN	2002:172363 USPATFULL
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
IN	<b>MacLean, David B.</b> , Providence, RI, UNITED STATES Thompson, David D., Gales Ferry, CT, UNITED STATES
PI	US 2002091121 A1 20020711 US 6613796 B2 20030902
AI	US 2001-999291 A1 20011115 (9)
RLI	Division of Ser. No. <u>US 2000-511806</u> , filed on 23 Feb 2000, PATENTED Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, PATENTED
PRAI	<u>US 1996-13212P</u> 19960228 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2060
INCL	INCLM: 514/217.010 INCLS: 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000
NCL	NCLM: 514/428.000
NCL	NCLM: 514/217.010 NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000

IC [7]  
 ICM: A61K031-55  
 ICS: A61K031-5513; A61K031-517; A61K031-506; A61K031-4709  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 8 OF 26 USPATFULL on STN

Full Text	Citing References
AN	2002:51000 USPATFULL
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
IN	<b>Maclean, David B.</b> , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer, Inc., New York, NY, United States (U.S. corporation)
PI	US 6355670 B1 20020312
AI	US 2000-511806 20000223 (9)
RLI	Continuation of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997
PRAI	<u>US 1996-13212P</u> 19960228 (60)
DT	Utility
FS	GRANTED
LN.CNT	2011
INCL	INCLM: 514/428.000 INCLS: 514/343.000; 514/319.000
NCL	NCLM: 514/428.000 NCLS: 514/319.000; 514/343.000

IC [7]  
 ICM: A61K031-40  
 ICS: A61K031-44; A61K031-445  
 EXF 514/319; 514/428; 514/343  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 9 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:48646 USPATFULL  
 TI Use of growth hormone secretagogues for treatment of physical performance decline  
 IN **MacLean, David B.**, Providence, RI, UNITED STATES  
 Landschulz, William H., East Lyme, CT, UNITED STATES  
 PI US 2002028838 A1 20020307  
 AI US 2001-892702 A1 20010627 (9)  
 PRAI US 2000-214980P 20000629 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1964  
 INCL INCLM: 514/354.000  
 INCLS: 514/423.000; 514/255.060  
 NCL NCLM: 514/354.000  
 NCLS: 514/255.060; 514/423.000  
 IC [7]  
 ICM: A61K031-497  
 ICS: A61K031-44; A61K031-401  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 10 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:145314 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions  
 IN **Maclean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PI US 2001018451 A1 20010830  
US 6403611 B2 20020611  
 AI US 2001-803516 A1 20010309 (9)  
 RLI Continuation of Ser. No. US 1999-314758, filed on 19 May 1999, PENDING  
 Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED,  
 Pat. No. US 6107331  
 PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2063  
 INCL INCLM: 514/428.000  
 INCLS: 514/320.000; 514/304.000  
 NCL NCLM: 514/315.000  
 NCL NCLM: 514/428.000  
 NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000  
 IC [7]  
 ICM: A61K031-445  
 ICS: A61K031-46  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 11 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:131333 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)  
 PI US 6274618 B1 20010814

AI US 1999-314758 19990519 (9)  
RLI Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, now  
 patented, Pat. No. US 6107331  
PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1933  
 INCL INCLM: 514/428.000  
 INCLS: 514/213.000; 514/317.000; 514/331.000  
 NCL NCLM: 514/428.000  
 NCLS: 514/317.000; 514/331.000  
 IC [7]  
 ICM: A61K031-40  
 ICS: A01N043-36  
 EXF 514/317; 514/213; 514/331; 514/428  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 12 OF 26 USPATFULL on STN

Full Text	References
--------------	------------

AN 2000:109836 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting  
 pathological conditions  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6107331 20000822  
AI US 1997-803733 19970221 (8)  
PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1927  
 INCL INCLM: 514/428.000  
 INCLS: 514/427.000  
 NCL NCLM: 514/428.000  
 NCLS: 514/427.000  
 IC [7]  
 ICM: A61K031-40  
 EXF 514/427; 514/428  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 26 USPATFULL on STN

Full Text	References
--------------	------------

AN 2000:102333 USPATFULL  
 TI Combination therapy to treat osteoporosis-polyphosphonates and estrogen  
 agonists  
 IN **Maclean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)  
PI US 6100301 20000808  
AI US 1998-92100 19980605 (9)  
PRAI US 1996-12409P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 743  
 INCL INCLM: 514/648.000  
 INCLS: 514/012.000  
 NCL NCLM: 514/648.000  
 NCLS: 514/012.000

IC [7]  
 ICM: A61K031-135  
 ICS: A61K038-00  
 EXF 514/648; 514/12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 14 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2000:54092 USPATFULL  
 TI Combination therapy to prevent bone loss-progesterone and estrogen agonists  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6057309 20000502  
 AI US 1998-193265 19981116 (9)  
 RLI Continuation of Ser. No. US 1997-803710, filed on 21 Feb 1997, now abandoned  
 PRAI US 1996-12400P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 438  
 INCL INCLM: 514/171.000  
 INCLS: 514/648.000  
 NCL NCLM: 514/171.000  
 NCLS: 514/648.000  
 IC [7]  
 ICM: A61K031-56  
 ICS: A61K031-135  
 EXF 514/648; 514/171  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 15 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2000:9953 USPATFULL  
 TI Method of increasing testosterone  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6017964 20000125  
 AI US 1998-208729 19981209 (9)  
 RLI Continuation of Ser. No. US 1997-803711, filed on 21 Feb 1997, now abandoned  
 PRAI US 1996-21181P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 348  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 16 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1999:146631 USPATFULL

TI Inhibition of autoimmune diseases  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)  
PI US 5985932 19991116  
AI US 1997-804346 19970221 (8)  
PRAI US 1996-12402P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 392  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 17 OF 26 USPATFULL on STN

Full Text	References
-----------	------------

AN 1999:40459 USPATFULL  
 TI Method of treating diseases and conditions with estrogen agonists and antagonists  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 5889042 19990330  
AI US 1997-803706 19970221 (8)  
PRAI US 1996-13213P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1668  
 INCL INCLM: 514/127.000  
 NCL NCLM: 514/427.000  
 IC [6]  
 ICM: A61K031-40  
 EXF 514/427  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 18 OF 26 USPATFULL on STN

Full Text	References
-----------	------------

AN 1999:7425 USPATFULL  
 TI Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 5861438 19990119  
AI US 1997-803712 19970221 (8)  
PRAI US 1996-12399P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 530  
 INCL INCLM: 514/648.000  
 INCL INCLS: 514/012.000  
 NCL NCLM: 514/648.000  
 NCL INCLS: 514/012.000  
 IC [6]  
 ICM: A61K038-00

ICS: A61K031-135  
 EXF 514/12; 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 19 OF 26 USPATFULL on STN

Full Text	Citing References
AN	1998:75623 USPATFULL
TI	Combination therapy to treat osteoporosis - polyphosphonates and estrogen agonists
IN	<b>MacLean, David B.</b> , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	US 5773477 19980630
AI	US 1997-803707 19970221 (8)
PRAI	US 1996-12409P 19960228 (60)
DT	Utility
FS	Granted
LN.CNT	499
INCL	INCLM: 514/648.000 INCLS: 514/102.000; 514/108.000
NCL	NCLM: 514/648.000 NCLS: 514/102.000; 514/108.000
IC	[6] ICM: A61K031-135 ICS: A61K031-66
EXF	514/648; 514/102; 514/108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L1 ANSWER 20 OF 26 USPATFULL on STN

Full Text	Citing References
AN	1998:33959 USPATFULL
TI	Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IN	<b>MacLean, David B.</b> , Providence County, RI, United States Thompson, David D., New London County, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	US 5733937 19980331
AI	US 1997-804702 19970221 (8)
PRAI	US 1996-12410P 19960228 (60)
DT	Utility
FS	Granted
LN.CNT	363
INCL	INCLM: 514/648.000
NCL	NCLM: 514/648.000
IC	[6] ICM: A61K031-135
EXF	514/648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L1 ANSWER 21 OF 26 USPATFULL on STN

Full Text	Citing References
AN	1998:25261 USPATFULL
TI	Protection of ischemic myocardium against reperfusion damage
IN	<b>MacLean, David B.</b> , Groton, CT, United States Thompson, David D., Groton, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	US 5726207 19980310

AI US 1997-805040 19970221 (8)  
 PRAI US 1996-12401P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 303  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/646  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 22 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:17354 USPATFULL  
 TI 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease  
 IN **Maclean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5719191 19980217  
 AI US 1997-805039 19970221 (8)  
 PRAI US 1996-25201P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 424  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 23 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:17353 USPATFULL  
 TI Inhibition of myeloperoxidase activity  
 IN **MacLean, David B.**, Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5719190 19980217  
 AI US 1997-803709 19970221 (8)  
 PRAI US 1986-12403P 19860228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 362  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 24 OF 26 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2003:312744 USPAT2  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

IN **MacLean, David B.**, Providence, RI, UNITED STATES  
 Thompson, David D., Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc, New York, NY, UNITED STATES (U.S. corporation)  
 PI US 6911456 B2 20050628  
 AI US 2002-133006 20020426 (10)  
 RLI Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, Pat. No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, Pat. No. US 6107331  
 PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2014  
 INCL INCLM: 514/315.000  
 INCLS: 514/428.000; 514/429.000  
 NCL NCLM: 514/315.000  
 NCL NCLM: 514/256.000  
 NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000; 514/394.000; 514/415.000  
 IC [7]  
 ICM: A61K031-445  
 EXF 514/315; 514/428; 514/429  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 25 OF 26 USPAT2 on STN

Full Text	Citing References
AN 2002:172363	USPAT2
TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions	
IN <b>Maclean, David B.</b> , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States	
PA Pfizer Inc., New York, NY, United States (U.S. corporation)	
PI <u>US 6613796</u> B2 20030902	
AI <u>US 2001-999291</u> 20011115 (9)	
RLI Division of Ser. No. <u>US 2000-511806</u> , filed on 3 Feb 2000, now patented, Pat. No. <u>US 6355670</u> Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, now patented, Pat. No. <u>US 6107331</u>	
PRAI <u>US 1996-13212P</u> 19960228 (60)	
DT Utility	
FS GRANTED	
LN.CNT 2003	
INCL INCLM: 514/428.000 INCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000	
NCL NCLM: 514/428.000	
NCL NCLM: 514/217.010 NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000	
IC [7] ICM: A61K031-40 ICS: A61K031-445; A61K031-44	
EXF 514/428; 514/429; 514/343; 514/319; 514/315	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L1 ANSWER 26 OF 26 USPAT2 on STN

Full Text	Citing References
AN 2001:145314	USPAT2
TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions	

IN Maclean, David B., Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6403611 B2 20020611  
 AI US 2001-803516 20010309 (9)  
 RLI Continuation of Ser. No. US 1999-314758, filed on 19 May 1999, now  
 patented, Pat. No. US 6274618 Continuation of Ser. No. US 1997-803733,  
 filed on 21 Feb 1997, now patented, Pat. No. US 6107331  
 PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2014  
 INCL INCLM: 514/315.000  
 INCLS: 514/428.000; 514/429.000  
 NCL NCLM: 514/315.000  
 NCL NCLM: 514/428.000  
 NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000  
 IC [7]  
 ICM: A61K031-445  
 EXF 514/429; 514/428; 514/315  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> @ thompson d/in

E1	2	THOMPSON CYNTHIA W/IN
E2	6	THOMPSON CYRIL V/IN
E3	0 -->	THOMPSON D/IN
E4	1	THOMPSON D F TOMMY/IN
E5	6	THOMPSON D SCOTT/IN
E6	1	THOMPSON DACID A/IN
E7	1	THOMPSON DALE E/IN
E8	4	THOMPSON DALE F/IN
E9	2	THOMPSON DALE G/IN
E10	1	THOMPSON DALE J/IN
E11	1	THOMPSON DALLAS A/IN
E12	1	THOMPSON DALLAS GLEN/IN

=> @

E13	2	THOMPSON DALTON/IN
E14	1	THOMPSON DAN/IN
E15	4	THOMPSON DANIEL/IN
E16	2	THOMPSON DANIEL A/IN
E17	2	THOMPSON DANIEL E/IN
E18	4	THOMPSON DANIEL G/IN
E19	2	THOMPSON DANIEL GEORGE/IN
E20	9	THOMPSON DANIEL J/IN
E21	11	THOMPSON DANIEL L/IN
E22	11	THOMPSON DANIEL LEE/IN
E23	2	THOMPSON DANIEL MARK/IN
E24	1	THOMPSON DANIEL P/IN

=> @

E25	2	THOMPSON DANIEL R/IN
E26	1	THOMPSON DANIEL SCOTT/IN
E27	34	THOMPSON DANIEL T/IN
E28	3	THOMPSON DANIEL W/IN
E29	1	THOMPSON DANNA D/IN
E30	2	THOMPSON DANNY B/IN
E31	5	THOMPSON DANNY C/IN
E32	2	THOMPSON DANNY CHARLES/IN

E33 7 THOMPSON DANNY L/IN  
 E34 10 THOMPSON DANNY R/IN  
 E35 1 THOMPSON DANNY W/IN  
 E36 2 THOMPSON DARRELL/IN

=> e

E37 1 THOMPSON DARRELL D/IN  
 E38 2 THOMPSON DARRELL L/IN  
 E39 13 THOMPSON DARRELL R/IN  
 E40 3 THOMPSON DARRELL T/IN  
 E41 2 THOMPSON DARREN/IN  
 E42 10 THOMPSON DARREN M/IN  
 E43 1 THOMPSON DARROW/IN  
 E44 2 THOMPSON DARROW D/IN  
 E45 2 THOMPSON DARYL L/IN  
 E46 1 THOMPSON DAVE/IN  
 E47 47 THOMPSON DAVID/IN  
 E48 65 THOMPSON DAVID A/IN

=> e

E49 4 THOMPSON DAVID ALLEN/IN  
 E50 6 THOMPSON DAVID B/IN  
 E51 9 THOMPSON DAVID C/IN  
 E52 3 THOMPSON DAVID CHARLES/IN  
 E53 1 THOMPSON DAVID CLYDE/IN  
 E54 78 THOMPSON DAVID D/IN  
 E55 6 THOMPSON DAVID E/IN  
 E56 2 THOMPSON DAVID EUGENE/IN  
 E57 27 THOMPSON DAVID F/IN  
 E58 1 THOMPSON DAVID FRANCIS/IN  
 E59 11 THOMPSON DAVID G/IN  
 E60 1 THOMPSON DAVID GALE/IN

=> \* e54

L2 78 "THOMPSON DAVID D"/IN

=> d 1-78

L2 ANSWER 1 OF 78 USPATFULL on STN

Full Text	References
-----------	------------

AN 2005:171876 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions  
 IN MacLean, David B., Providence, RI, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc (U.S. corporation)  
 PI US 2005148625 A1 20050707  
 AI US 2005-71955 A1 20050303 (11)  
 RLI Division of Ser. No. US 2002-133006, filed on 26 Apr 2002, PENDING  
 Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, GRANTED, Pat. No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331  
 PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1986  
 INCL INCLM: 514/310.000  
 INCLS: 514/319.000; 514/343.000; 514/408.000

NCL NCLM: 514/310.000  
 NCLS: 514/319.000; 514/343.000; 514/408.000  
 IC [7]  
 ICM: A61K031-4709  
 ICS: A61K031-454; A61K031-4439; A61K031-40  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 78 USPATFULL on STN

Full Text	References
AN	2005:93420 USPATFULL
TI	Methods and kits for treating depression or preventing deterioration of cognitive function
IN	Day, Wesley W., San Diego, CA, UNITED STATES Lee, Andrew G., Old Lyme, CT, UNITED STATES <b>Thompson, David D.</b> , Gales Ferry, CT, UNITED STATES Petrie, Charles D., Cranston, RI, UNITED STATES
PA	Pfizer Inc (U.S. corporation)
PI	US 2005080099 A1 20050414
AI	US 2004-956896 A1 20040930 (10)
RLI	Division of Ser. No. <u>US 2002-132907</u> , filed on 24 Apr 2002, ABANDONED
PRAI	US 2001-286433P 20010425 (60)
DT	Utility
FS	APPLICATION
LN.CNT	1554
INCL	INCLM: 514/266.200 INCLS: 514/275.000; 514/314.000; 514/310.000
NCL	NCLM: 514/266.200 NCLS: 514/275.000; 514/310.000; 514/314.000
IC	[7] ICM: A61K031-517 ICS: A61K031-505; A61K031-4709 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 78 USPATFULL on STN

Full Text	References
AN	2005:75833 USPATFULL
TI	2-alkylidene-19-nor-vitamin D derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
IN	<b>Thompson, David D.</b> , Gales Ferry, CT, UNITED STATES
PA	Pfizer Inc (U.S. corporation)
PI	US 2005065134 A1 20050324
AI	US 2004-944368 A1 20040916 (10)
PRAI	US 2003-504510P 20030919 (60)
DT	Utility
FS	APPLICATION
LN.CNT	1104
INCL	INCLM: 514/167.000
NCL	NCLM: 514/167.000
IC	[7] ICM: A61K031-59 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 78 USPATFULL on STN

Full Text	References
AN	2005:75832 USPATFULL
TI	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective

agonist  
 IN Lee, Andrew G., Old Lyme, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc (U.S. corporation)  
 PI US 2005065133 A1 20050324  
 AI US 2004-944119 A1 20040916 (10)  
 PRAI US 2003-503798P 20030919 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4480  
 INCL INCLM: 514/167.000  
 INCLS: 514/345.000  
 NCL NCLM: 514/167.000  
 NCLS: 514/345.000  
 IC [7]  
 ICM: A61K031-59  
 ICS: A61K031-44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75831 USPATFULL  
 TI 2-alkylidene-19-nor-vitamin D derivatives for the treatment or prevention of a secon hip fracture  
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc (U.S. corporation)  
 PI US 2005065132 A1 20050324  
 AI US 2004-944065 A1 20040916 (10)  
 PRAI US 2003-504004P 20030919 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1121  
 INCL INCLM: 514/167.000  
 NCL NCLM: 514/167.000  
 IC [7]  
 ICM: A61K031-59  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75830 USPATFULL  
 TI 2-alkylidene-19-nor-vitamin D derivatives for enhancement of peak bone mass in adolescence  
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc (U.S. corporation)  
 PI US 2005065131 A1 20050324  
 AI US 2004-944063 A1 20040916 (10)  
 PRAI US 2003-504511P 20030919 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1112  
 INCL INCLM: 514/167.000  
 NCL NCLM: 514/167.000  
 IC [7]  
 ICM: A61K031-59  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75829 USPATFULL  
 TI Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a cyclooxygenase-2 inhibitor  
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc. (U.S. corporation)  
 PI US 2005065130 A1 20050324  
 AI US 2004-943561 A1 20040916 (10)  
 PRAI US 2003-504003P 20030919 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1536  
 INCL INCLM: 514/167.000  
 INCLS: 514/406.000; 514/378.000  
 NCL NCLM: 514/167.000  
 NCLS: 514/378.000; 514/406.000  
 IC [7]  
 ICM: A61K031-59  
 ICS: A61K031-42; A61K031-415  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75787 USPATFULL  
 TI Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone  
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc. (U.S. corporation)  
 PI US 2005065088 A1 20050324  
 AI US 2004-946585 A1 20040916 (10)  
 PRAI US 2003-504503P 20030919 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1427  
 INCL INCLM: 514/012.000  
 INCLS: 514/167.000  
 NCL NCLM: 514/012.000  
 NCLS: 514/167.000  
 IC [7]  
 ICM: A61K038-29  
 ICS: A61K031-59  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:328061 USPATFULL  
 TI Compositions and methods for treating osteoporosis and lowering cholesterol  
 IN Day, Wesley W., San Diego, CA, UNITED STATES  
 Lee, Andrew G., Old Lyme, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc (U.S. corporation)  
 PI US 2004259886 A1 20041223  
 AI US 2004-840577 A1 20040506 (10)  
 RLI Division of Ser. No. US 2001-767625, filed on 23 Jan 2001, GRANTED, Pat. No. US 6756401

PRAI US 2000-188923P 20000126 (60)  
 US 2000-205327P 20000421 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1856  
 INCL INCLM: 514/256.000  
 INCLS: 514/266.200; 514/266.210; 514/423.000; 514/460.000; 514/548.000  
 NCL NCLM: 514/256.000  
 NCLS: 514/266.200; 514/266.210; 514/423.000; 514/460.000; 514/548.000  
 IC [7]  
 ICM: A61K031-517  
 ICS: A61K031-506; A61K031-401  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	2004:228075	USPATFULL
TI	Prevention of loss and restoration of bone mass by certain prostaglandin agonists	
IN	Cameron, Kimberly O., East Lyme, CT, UNITED STATES Ke, Hua Z., Ledyard, CT, UNITED STATES Lefker, Bruce A., Gales Ferry, CT, UNITED STATES Rosati, Robert L., Mystic, CT, UNITED STATES <b>Thompson, David D.</b> , Gales Ferry, CT, UNITED STATES	
PA	Pfizer Inc (U.S. corporation)	
PI	US 2004176461	A1 20040909
AI	US 2003-652188	A1 20030829 (10)
RLI	Division of Ser. No. <u>US 2002-256985</u> , filed on 26 Sep 2002, GRANTED, Pat. No. <u>US 6649657</u> Division of Ser. No. <u>US 2001-897824</u> , filed on 29 Jun 2001, GRANTED, Pat. No. <u>US 6492412</u> Division of Ser. No. <u>US 1999-331081</u> , filed on 11 Jun 1999, GRANTED, Pat. No. <u>US 6288120</u> A 371 of International Ser. No. <u>WO 1997-IB1417</u> , filed on 10 Nov 1997, UNKNOWN	
<u>PRAI</u>	<u>US 1996-33451P</u>	19961220 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	9724	
INCL	INCLM: 514/602.000 INCLS: 514/478.000; 560/012.000; 564/086.000	
NCL	NCLM: 514/602.000 NCLS: 514/478.000; 560/012.000; 564/086.000	
IC	[7] ICM: A61K031-325 ICS: A61K031-185; A61K031-18	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 11 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	2004:121090	USPATFULL
TI	Compositions and methods for treating conditions responsive to estrogen	
IN	<b>Thompson, David D.</b> , Gales Ferry, CT, UNITED STATES Lee, Andrew G., Old Tyme, CT, UNITED STATES Day, Wesley W., Old Tyme, CT, UNITED STATES Rosati, Robert L., Stonington, CT, UNITED STATES	
PA	Pfizer Inc (U.S. corporation)	
PI	US 2004092506	A1 20040513
AI	US 2003-652186	A1 20030829 (10)
RLI	Division of Ser. No. <u>US 2001-758778</u> , filed on 11 Jan 2001, GRANTED, Pat. No. <u>US 6632834</u>	

PRAI US 2000-175752P 20000112 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2385  
 INCL INCLM: 514/217.060  
 INCLS: 514/217.070; 514/228.200; 514/234.200; 514/235.800; 514/266.200;  
 514/256.000; 514/307.000; 514/314.000; 514/252.170; 514/252.180  
 NCL NCLM: 514/217.060  
 NCLS: 514/217.070; 514/228.200; 514/234.200; 514/235.800; 514/252.170;  
 514/252.180; 514/256.000; 514/266.200; 514/307.000; 514/314.000  
 IC [7]  
 ICM: A61K031-55  
 ICS: A61K031-541; A61K031-5377; A61K031-517; A61K031-506; A61K031-4709  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 78 USPATFULL on STN

Full Text	Citing References
AN 2004:13471 USPATFULL	
TI Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions	
IN MacLean, David B., Providence, RI, UNITED STATES Thompson, David D., Gales Ferry, CT, UNITED STATES	
PA Pfizer Inc. (U.S. corporation)	
PI <u>US 2004009994</u> A1 20040115	
AI <u>US 2003-615282</u> A1 20030707 (10)	
RLI Division of Ser. No. <u>US 2001-999291</u> , filed on 15 Nov 2001, GRANTED, Pat. No. <u>US 6613796</u> Division of Ser. No. <u>US 2000-511806</u> , filed on 23 Feb 2000, GRANTED, Pat. No. <u>US 6355670</u> Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, GRANTED, Pat. No. <u>US 6107331</u>	
PRAI <u>US 1996-13212P</u> 19960228 (60)	
DT Utility	
FS APPLICATION	
LN.CNT 2058	
INCL INCLM: 514/266.200 INCLS: 514/266.220; 514/256.000; 514/307.000; 514/314.000	
NCL NCLM: 514/266.200 NCLS: 514/256.000; 514/266.220; 514/307.000; 514/314.000	
IC [7] ICM: A61K031-517 ICS: A61K031-506; A61K031-4709	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 13 OF 78 USPATFULL on STN

Full Text	Citing References
AN 2003:312744 USPATFULL	
TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions	
IN MacLean, David B., Providence, RI, UNITED STATES Thompson, David D., Gales Ferry, CT, UNITED STATES	
PI <u>US 2003220349</u> A1 20031127 <u>US 6911456</u> B2 20050628	
AI <u>US 2002-133006</u> A1 20020426 (10)	
RLI Division of Ser. No. <u>US 2001-803516</u> , filed on 9 Mar 2001, GRANTED, Pat. No. <u>US 6403611</u> Division of Ser. No. <u>US 2000-511806</u> , filed on 23 Feb 2000, GRANTED, Pat. No. <u>US 6355670</u> Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, GRANTED, Pat. No. <u>US 6107331</u>	
PRAI <u>US 1996-13212P</u> 19960228 (60)	
DT Utility	

## FS APPLICATION

LN.CNT 2038

INCL INCLM: 514/256.000

INCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000;  
514/394.000; 514/415.000

NCL NCLM: 514/315.000

NCL NCLM: 514/256.000

NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000;  
514/314.000; 514/339.000; 514/394.000; 514/415.000

IC [7]

ICM: A61K031-517

ICS: A61K031-506; A61K031-4709; A61K031-4184; A61K031-4439; A61K031-404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2003:238473 USPATFULL
TI	Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
IN	Dumont, Francis, Ledyard, CT, UNITED STATES Hong, Jinyang, Stonington, CT, UNITED STATES Kim, Yesook, Branford, CT, UNITED STATES Korsmeyer, Richard W., Old Lyme, CT, UNITED STATES Li, Mei, Westerly, RI, UNITED STATES Paralkar, Vishwas M., Madison, CT, UNITED STATES <b>Thompson, David D.</b> , Gales Ferry, CT, UNITED STATES
PI	<u>US 2003166631</u> A1 20030904
AI	<u>US 2002-305649</u> A1 20021126 (10)
PRAI	<u>US 2001-335156P</u> 20011130 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2593
INCL	INCLM: 514/211.010 INCLS: 514/478.000; 514/521.000; 514/603.000; 514/227.500; 514/255.030; 514/317.000; 514/237.800; 514/218.000; 514/217.120; 514/365.000; 514/374.000; 514/408.000; 514/400.000
NCL	NCLM: 514/211.010 NCLS: 514/217.120; 514/218.000; 514/227.500; 514/237.800; 514/255.030; 514/317.000; 514/365.000; 514/374.000; 514/400.000; 514/408.000; 514/478.000; 514/521.000; 514/603.000
IC	[7] ICM: A61K031-55 ICS: A61K031-553; A61K031-554; A61K031-54; A61K031-537; A61K031-496; A61K031-426; A61K031-421

AN 2003:238473 USPATFULL

TI Pharmaceutical compositions and methods for administering EP2 receptor selective agonists

IN Dumont, Francis, Ledyard, CT, UNITED STATES  
Hong, Jinyang, Stonington, CT, UNITED STATES  
Kim, Yesook, Branford, CT, UNITED STATES  
Korsmeyer, Richard W., Old Lyme, CT, UNITED STATES  
Li, Mei, Westerly, RI, UNITED STATES  
Paralkar, Vishwas M., Madison, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATESPI US 2003166631 A1 20030904AI US 2002-305649 A1 20021126 (10)PRAI US 2001-335156P 20011130 (60)

DT Utility

FS APPLICATION

LN.CNT 2593

INCL INCLM: 514/211.010

INCLS: 514/478.000; 514/521.000; 514/603.000; 514/227.500; 514/255.030;  
514/317.000; 514/237.800; 514/218.000; 514/217.120; 514/365.000;  
514/374.000; 514/408.000; 514/400.000

NCL NCLM: 514/211.010

NCLS: 514/217.120; 514/218.000; 514/227.500; 514/237.800; 514/255.030;  
514/317.000; 514/365.000; 514/374.000; 514/400.000; 514/408.000;  
514/478.000; 514/521.000; 514/603.000

IC [7]

ICM: A61K031-55

ICS: A61K031-553; A61K031-554; A61K031-54; A61K031-537; A61K031-496;  
A61K031-426; A61K031-421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2003:232606 USPATFULL
TI	Compositions and methods for treating osteoporosis and lowering cholesterol
IN	Day, Wesley W., Old Lyme, CT, UNITED STATES Lee, Andrew G., Old Lyme, CT, UNITED STATES <b>Thompson, David D.</b> , Gales Ferry, CT, UNITED STATES
PI	<u>US 2003162807</u> A1 20030828 <u>US 6756401</u> B2 20040629
AI	<u>US 2001-767625</u> A1 20010123 (9)
PRAI	<u>US 2000-188293P</u> 20000308 (60)

AN 2003:232606 USPATFULL

TI Compositions and methods for treating osteoporosis and lowering cholesterol

IN Day, Wesley W., Old Lyme, CT, UNITED STATES  
Lee, Andrew G., Old Lyme, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATESPI US 2003162807 A1 20030828US 6756401 B2 20040629AI US 2001-767625 A1 20010123 (9)PRAI US 2000-188293P 20000308 (60)

US 2000-205327P 20000421 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1958  
 INCL INCLM: 514/307.000  
 INCLS: 514/319.000; 514/412.000; 514/408.000  
 NCL NCLM: 514/428.000  
 NCL NCLM: 514/307.000  
 NCLS: 514/461.000; 514/473.000; 514/319.000; 514/408.000; 514/412.000  
 IC [7]  
 ICM: A61K031-40  
 ICS: A61K031-445  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2003:181486 USPATFULL  
 TI Methods for assessing, improving, or maintaining urogenital health in postmenopausal women  
 IN Day, Wesley W., San Diego, CA, UNITED STATES  
 Lee, Andrew G., Old Lyme, CT, UNITED STATES  
 Thompson, David D., Gales Ferry, CT, UNITED STATES  
 PI US 2003125319 A1 20030703  
 AI US 2002-292203 A1 20021112 (10)  
 RLI Division of Ser. No. US 2001-976825, filed on 12 Oct 2001, PENDING  
 PRAI US 2000-240789P 20001016 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4739  
 INCL INCLM: 514/217.060  
 INCLS: 514/217.070; 514/256.000; 514/266.200; 514/266.220; 514/228.200; 514/232.800; 514/252.170; 514/252.180; 514/314.000; 514/319.000; 514/318.000  
 NCL NCLM: 514/217.060  
 NCLS: 514/217.070; 514/228.200; 514/232.800; 514/252.170; 514/252.180; 514/256.000; 514/266.200; 514/266.220; 514/314.000; 514/318.000; 514/319.000  
 IC [7]  
 ICM: A61K031-55  
 ICS: A61K031-541; A61K031-5377; A61K031-517; A61K031-506; A61K031-496; A61K031-4709; A61K031-4545  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2003:166582 USPATFULL  
 TI Compositions and methods of treatment for conditions responsive to testosterone elevation  
 IN Lee, Andrew G., Old Lyme, CT, UNITED STATES  
 Day, Wesley W., Old Lyme, CT, UNITED STATES  
 Thompson, David D., Gales Ferry, CT, UNITED STATES  
 PI US 2003114440 A1 20030619  
 AI US 2002-301930 A1 20021121 (10)  
 RLI Division of Ser. No. US 2001-757423, filed on 10 Jan 2001, GRANTED, Pat. No. US 6512002  
 PRAI US 2000-175704P 20000112 (60)  
 DT Utility  
 FS APPLICATION

LN.CNT 2198

INCL INCLM: 514/217.060

INCLS: 514/217.070; 514/256.000; 514/266.200; 514/266.220; 514/252.170;  
514/252.180; 514/314.000; 514/318.000; 514/319.000; 514/649.000;  
514/228.200; 514/232.800; 514/233.800

NCL NCLM: 514/217.060

NCLS: 514/217.070; 514/228.200; 514/232.800; 514/233.800; 514/252.170;  
514/252.180; 514/256.000; 514/266.200; 514/266.220; 514/314.000;  
514/318.000; 514/319.000; 514/649.000

IC [7]

ICM: A61K031-55

ICS: A61K031-541; A61K031-5377; A61K031-517; A61K031-496; A61K031-506;  
A61K031-4709; A61K031-137; A61K031-4545

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 18 OF 78 USPATFULL on STN

Full  
TextCiting  
References

AN 2003:153424 USPATFULL

TI Prevention of loss and restoration of bone mass by certain prostaglandin  
agonists

IN Cameron, Kimberley Q., East Lyme, CT, UNITED STATES

Ke, Hua Z., Ledyard, CT, UNITED STATES

Lefker, Bruce A., Gales Ferry, CT, UNITED STATES

Rosati, Robert L., Mystic, CT, UNITED STATES

**Thompson, David D.**, Gales Ferry, CT, UNITED STATESPI US 2003105092 A1 20030605US 6649657 B2 20031118AI US 2002-256985 A1 20020926 (10)RLI Division of Ser. No. US 2001-897824, filed on 29 Jun 2001, GRANTED, Pat.  
No. US 6492412

DT Utility

FS APPLICATION

LN.CNT 9746

INCL INCLM: 514/227.500

INCLS: 514/238.200; 514/252.100; 514/357.000; 514/365.000; 514/385.000;  
514/399.000; 514/406.000; 514/602.000; 544/059.000; 544/159.000;  
544/402.000; 546/334.000; 548/193.000; 548/235.000; 548/335.500;  
564/095.000

NCL NCLM: 514/545.000

NCL NCLM: 514/227.500

NCLS: 514/438.000; 514/461.000; 514/570.000; 549/070.000; 549/484.000;  
560/051.000; 562/459.000; 514/238.200; 514/252.100; 514/357.000;  
514/365.000; 514/385.000; 514/399.000; 514/406.000; 514/602.000;  
544/059.000; 544/159.000; 544/402.000; 546/334.000; 548/193.000;  
548/235.000; 548/335.500; 564/095.000

IC [7]

ICM: A61K031-54

ICS: A61K031-537; A61K031-495; A61K031-44; A61K031-426; A61K031-421;  
A61K031-4172; A61K031-18

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 19 OF 78 USPATFULL on STN

Full  
TextCiting  
References

AN 2003:134630 USPATFULL

TI Methods and kits for treating depression or preventing deterioration of  
cognitive function

IN Day, Wesley W., San Diego, CA, UNITED STATES

Lee, Andrew G., Old Lyme, CT, UNITED STATES

**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
**Petrie, Charles D.**, Cranston, RI, UNITED STATES

PI US 2003092719 A1 20030515  
AI US 2002-132907 A1 20020424 (10)  
PRAI US 2001-286433P 20010425 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1868  
 INCL INCLM: 514/256.000  
 INCLS: 514/266.200; 514/266.100; 514/266.210; 514/314.000; 514/307.000;  
 514/337.000; 514/732.000  
 NCL NCLM: 514/256.000  
 NCLS: 514/266.100; 514/266.200; 514/266.210; 514/307.000; 514/314.000;  
 514/337.000; 514/732.000  
 IC [7]  
 ICM: A61K031-505  
 ICS: A61K031-517; A61K031-47; A61K031-4709; A61K031-4439; A61K031-05  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2003:93656 USPATFULL  
 TI Pharmaceutical compositions, kits and methods comprising combinations of  
 estrogen agonists / antagonists, estrogens and progestins  
 IN HuaZhu, Ke, Ledyard, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
PI US 2003065017 A1 20030403  
AI US 2002-206587 A1 20020726 (10)  
PRAI US 2001-309065P 20010731 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1342  
 INCL INCLM: 514/408.000  
 NCL NCLM: 514/408.000  
 IC [7]  
 ICM: A61K031-40  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 21 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:280644 USPATFULL  
 TI Methods and kits for improving vascular health  
 IN Day, Wesley W., San Diego, CA, UNITED STATES  
 Lee, Andrew G., Old Lyme, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
PI US 2002156090 A1 20021024  
 US 6620806 B2 20030916  
AI US 2001-977458 A1 20011015 (9)  
PRAI US 2000-241532P 20001017 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2950  
 INCL INCLM: 514/266.200  
 INCLS: 514/266.210; 514/256.000; 514/314.000; 514/307.000; 514/337.000;  
 514/394.000; 514/415.000  
 NCL NCLM: 514/217.030  
 NCL NCLM: 514/266.200  
 NCLS: 514/211.150; 514/217.080; 514/218.000; 514/307.000; 514/315.000;

514/317.000; 514/323.000; 514/331.000; 514/345.000; 514/414.000;  
 514/415.000; 514/428.000; 514/582.000; 514/585.000; 514/648.000;  
 514/256.000; 514/266.210; 514/314.000; 514/337.000; 514/394.000

IC [7]

ICM: A61K031-517

ICS: A61K031-506; A61K031-4709; A61K031-47; A61K031-404; A61K031-4439

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 22 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2002:236078 USPATFULL

TI Methods for assessing, improving, or maintaining urogenital health in postmenopausal women

IN Day, Wesley W., San Diego, CA, UNITED STATES

Lee, Andrew W., Old Lyme, CT, UNITED STATES

**Thompson, David D.**, Gales Ferry, CT, UNITED STATES

PI US 2002128276 A1 20020912

AI US 2001-976825 A1 20011012 (9)

PRAI US 2000-240789P 20001016 (60)

DT Utility

FS APPLICATION

LN.CNT 4685

INCL INCLM: 514/256.000

INCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000

NCL NCLM: 514/256.000

NCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000

IC [7]

ICM: A61K031-517

ICS: A61K031-506; A61K031-4709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 23 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2002:209558 USPATFULL

TI Dosing regimens for lasofoxifene

IN **Thompson, David D.**, Gales Ferry, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6436977 B1 20020820

AI US 2000-656273 20000906 (9)

PRAI US 1999-156652P 19990929 (60)

DT Utility

FS GRANTED

LN.CNT 254

INCL INCLM: 514/367.000

INCLS: 514/377.000

NCL NCLM: 514/367.000

NCLS: 514/377.000

IC [7]

ICM: A61K031-425

ICS: A61K031-42

EXF 514/367; 514/377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 24 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2002:188358 USPATFULL

TI Prevention and treatment of skeletal disorder with EP2 receptor subtype

selective prostaglandin E2 agonists

IN Cameron, Kimberly O., East Lyme, CT, United States  
 Ke, Hua Z., Ledyard, CT, United States  
 Lefker, Bruce A., Gales Ferry, CT, United States  
 Rosati, Robert L, Mystic, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6426359 B1 20020730  
WO 9827976 19980702

AI US 1999-331078 19990611 (9)  
WO 1997-IB1483 19971127  
 19990611 PCT 371 date

PRAI US 1996-33569P 19961220 (60)

DT Utility

FS GRANTED

LN.CNT 2773

INCL INCLM: 514/381.000  
 INCLS: 514/488.000; 514/601.000; 435/366.000; 548/252.000; 548/254.000;  
 549/071.000; 568/030.000

NCL NCLM: 514/381.000  
 NCLS: 435/366.000; 514/488.000; 514/601.000; 548/252.000; 548/254.000;  
 549/071.000; 568/030.000

IC [7]  
 ICM: A61K031-41  
 ICS: C07C317-00; C07D257-04

EXF 514/381; 514/488; 514/601; 548/252; 548/254; 549/71; 568/30; 435/366

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 25 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:172363 USPATFULL

TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

IN MacLean, David B., Providence, RI, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES

PI US 2002091121 A1 20020711  
US 6613796 B2 20030902

AI US 2001-999291 A1 20011115 (9)

RLI Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, PATENTED  
 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, PATENTED

PRAI US 1996-13212P 19960228 (60)

DT Utility

FS APPLICATION

LN.CNT 2060

INCL INCLM: 514/217.010  
 INCLS: 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000;  
 514/314.000

NCL NCLM: 514/428.000

NCL NCLM: 514/217.010  
 NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000;  
 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000

IC [7]  
 ICM: A61K031-55  
 ICS: A61K031-5513; A61K031-517; A61K031-506; A61K031-4709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:73008 USPATFULL  
 TI EP4 receptor selective agonists in the treatment of osteoporosis  
 IN Cameron, Kimberly O., East Lyme, CT, UNITED STATES  
 Ke, HuaZhu, Ledyard, CT, UNITED STATES  
 Lefker, Bruce A., Gales Ferry, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PI US 2002040149 A1 20020404  
US 6642266 B2 20031104  
 AI US 2001-991585 A1 20011116 (9)  
 RLI Division of Ser. No. US 2000-738670, filed on 15 Dec 2000, PENDING  
 PRAI US 1999-171353P 19991222 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1849  
 INCL INCLM: 548/253.000  
 INCLS: 514/381.000; 514/424.000; 548/550.000; 548/551.000  
 NCL NCLM: 514/424.000  
 NCL NCLM: 548/253.000  
 NCLS: 514/381.000; 548/551.000; 548/550.000  
 IC [7]  
 ICM: A61K031-41  
 ICS: A61K031-4015; C07D043-02; C07D027-27  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:51000 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions  
 IN Maclean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer, Inc., New York, NY, United States (U.S. corporation)  
 PI US 6355670 B1 20020312  
 AI US 2000-511806 20000223 (9)  
 RLI Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997  
 PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2011  
 INCL INCLM: 514/428.000  
 INCLS: 514/343.000; 514/319.000  
 NCL NCLM: 514/428.000  
 NCLS: 514/319.000; 514/343.000  
 IC [7]  
 ICM: A61K031-40  
 ICS: A61K031-44; A61K031-445  
 EXF 514/319; 514/428; 514/343  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 28 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:27520 USPATFULL  
 TI Prevention of loss and restoration of bone mass by certain prostaglandin agonists  
 IN Cameron, Kimberly O., East Lyme, CT, UNITED STATES  
 Ke, Hua Z., Ledyard, CT, UNITED STATES  
 Lefker, Bruce A., Gales Ferry, CT, UNITED STATES  
 Rosati, Robert L., Mystic, CT, UNITED STATES

**Thompson, David D.**, Gales Ferry, CT, UNITED STATES

PI US 2002016368 A1 20020207  
 US 6492412 B2 20021210  
 AI US 2001-897824 A1 20010629 (9)  
 RLI Division of Ser. No. US 1999-331081, filed on 11 Jun 1999, GRANTED, Pat.  
 No. US 6288120 A 371 of International Ser. No. WO 1997-IB1417, filed on  
 10 Nov 1997, UNKNOWN  
 PRAI US 1996-33451P 19961220 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 9918  
 INCL INCLM: 514/601.000  
 INCLS: 514/575.000; 514/626.000; 514/665.000; 562/623.000; 564/095.000;  
 564/193.000; 564/440.000  
 NCL NCLM: 514/423.000  
 NCL NCLM: 514/601.000  
 NCLS: 514/252.100; 514/255.050; 514/256.000; 514/448.000; 514/570.000;  
 514/605.000; 544/335.000; 544/336.000; 548/531.000; 549/072.000;  
 562/470.000; 564/099.000; 514/575.000; 514/626.000; 514/665.000;  
 562/623.000; 564/095.000; 564/193.000; 564/440.000  
 IC [7]  
 ICM: A61K031-185  
 ICS: A61K031-18; A61K031-13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 29 OF 78 USPATFULL on STN

Full Text	Chng References
--------------	--------------------

AN 2002:22491 USPATFULL  
 TI Compositions and methods for treating female sexual dysfunction  
 IN Lee, Andrew G., Old Lyme, CT, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 Day, Wesley W., Old Lyme, CT, UNITED STATES  
 PI US 2002013327 A1 20020131  
 AI US 2001-833169 A1 20010411 (9)  
 PRAI US 2000-266387P 20000418 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2652  
 INCL INCLM: 514/256.000  
 INCLS: 514/259.000; 514/307.000; 514/314.000; 514/338.000; 514/339.000  
 NCL NCLM: 514/256.000  
 NCLS: 514/307.000; 514/314.000; 514/338.000; 514/339.000; 544/262.000  
 IC [7]  
 ICM: A61K031-517  
 ICS: A61K031-506; A61K031-4725; A61K031-4709; A61K031-4439  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 30 OF 78 USPATFULL on STN

Full Text	Chng References
--------------	--------------------

AN 2001:237979 USPATFULL  
 TI Method of reducing morbidity and the risk of mortality  
 IN Day, Wesley W., Old Lyme, CT, United States  
 Lee, Andrew G., Old Lyme, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PI US 2001056099 A1 20011227  
 AI US 2001-757817 A1 20010110 (9)  
 PRAI US 2000-175663P 20000112 (60)  
 DT Utility

FS APPLICATION  
 LN.CNT 1997  
 INCL INCLM: 514/307.000  
 INCLS: 514/319.000; 514/320.000; 514/408.000; 514/412.000  
 NCL NCLM: 514/307.000  
 NCLS: 514/319.000; 514/320.000; 514/408.000; 514/412.000  
 IC [7]  
 ICM: A61K031-453  
 ICS: A61K031-445; A61K031-40  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 31 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2001:237940 USPATFULL  
 TI Treatment of osteoporosis with EP2/EP4 receptor selective agonists  
 IN Cameron, Kimberly O., East Lyme, CT, United States  
 Ke, HuaZhu, Ledyard, CT, United States  
 Lefker, Bruce A., Gales Ferry, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PI US 2001056060 A1 20011227  
 AI US 2001-776430 A1 20010202 (9)  
 PRAI US 2000-180635P 20000207 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1737  
 INCL INCLM: 514/001.000  
 NCL NCLM: 514/001.000  
 IC [7]  
 ICM: A61K031-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 32 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2001:218612 USPATFULL  
 TI EP4 receptor selective agonists in the treatment of osteoporosis  
 IN Cameron, Kimberly O., East Lyme, CT, United States  
 Ke, HuaZhu, Ledyard, CT, United States  
 Lefker, Bruce A., Gales Ferry, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PI US 2001047105 A1 20011129  
US 6737437 B2 20040518  
 AI US 2000-738670 A1 20001215 (9)  
 PRAI US 1999-171353P 19991222 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1820  
 INCL INCLM: 560/001.000  
 INCLS: 514/381.000; 514/454.000; 548/253.000; 548/551.000  
 NCL NCLM: 514/424.000  
 NCL NCLM: 560/001.000  
 NCLS: 548/253.000; 548/551.000  
 IC [7]  
 ICM: C07D257-00  
 ICS: A61K031-41; A01N043-64; A61K031-35; A01N043-16; C07D207-12;  
 C07D207-24; C07D207-36  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 33 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:215078 USPATFULL  
 TI Combination therapy for osteoporosis  
 IN Ke, Hua Zhu, Ledyard, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6323232 B1 20011127  
WO 9731640 19970904  
 AI US 1998-117972 19980811 (9)  
WO 1996-IB1462 19961223  
 19980811 PCT 371 date  
 19980811 PCT 102(e) date  
 PRAI US 1996-12412P 19960228 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2001  
 INCL INCLM: 514/408.000  
 INCLS: 514/648.000; 514/443.000  
 NCL NCLM: 514/408.000  
 NCLS: 514/443.000; 514/648.000  
 IC [7]  
 ICM: A61K031-40  
 ICS: A61K031-13; A61K031-38  
 EXF 514/648; 514/443; 514/337; 514/257; 514/408  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 34 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:212438 USPATFULL  
 TI Compositions and methods of treatment for conditions responsive to testosterone elevation  
 IN Lee, Andrew G., Old Lyme, CT, United States  
 Day, Wesley W., Old Lyme, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PI US 2001044434 A1 20011122  
US 6512002 B2 20030128  
 AI US 2001-757423 A1 20010110 (9)  
 PRAI US 2000-175704P 20000112 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2192  
 INCL INCLM: 514/217.030  
 INCLS: 514/317.000; 514/217.080; 514/415.000; 514/648.000  
 NCL NCLM: 514/427.000  
 NCL NCLM: 514/217.030  
 NCLS: 514/410.000; 514/415.000; 514/428.000; 514/429.000; 514/217.080;  
 514/317.000; 514/648.000  
 IC [7]  
 ICM: A61K031-55  
 ICS: A61K031-454; A61K031-404; A61K031-135  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 35 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:205936 USPATFULL  
 TI Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure

IN Paralkar, Vishwas M., Madison, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PI US 2001041729 A1 20011115  
US 6610719 B2 20030826  
 AI US 2001-771164 A1 20010129 (9)  
 PRAI US 2000-178968P 20000131 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 671  
 INCL INCLM: 514/381.000  
 INCLS: 514/424.000  
 NCL NCLM: 514/381.000  
 NCL NCLM: 514/381.000  
 NCLS: 514/352.000; 514/423.000; 514/530.000; 514/573.000; 514/424.000  
 IC [7]  
 ICM: A61K031-41  
 ICS: A01N043-64; A61K031-40; A01N043-36  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 36 OF 78 USPATFULL on STN

Full Text	Citing References
AN 2001:205925	USPATFULL
TI Compositions and methods for treating conditions responsive to estrogen	
IN <b>Thompson, David D.</b> , Gales Ferry, CT, United States Lee, Andrew G., Old Lyme, CT, United States Day, Wesely W., Old Lyme, CT, United States Rosati, Robert L., Stonington, CT, United States	
PI <u>US 2001041718</u> A1 20011115 <u>US 6632834</u> B2 20031014	
AI <u>US 2001-758778</u> A1 20010111 (9)	
PRAI <u>US 2000-175752P</u> 20000112 (60)	
DT Utility	
FS APPLICATION	
LN.CNT 2385	
INCL INCLM: 514/317.000 INCLS: 514/308.000; 514/408.000	
NCL NCLM: 514/428.000	
NCL NCLM: 514/317.000 NCLS: 514/308.000; 514/408.000	
IC [7] ICM: A61K031-4725 ICS: A61K031-445; A61K031-40	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 37 OF 78 USPATFULL on STN

Full Text	Citing References
AN 2001:194421	USPATFULL
TI Compositions and methods for treating osteoporosis	
IN Day, Wesley W., Old Lyme, CT, United States <b>Thompson, David D.</b> , Gales Ferry, CT, United States Lee, Andrew G., Old Lyme, CT, United States	
PI <u>US 2001036936</u> A1 20011101	
AI <u>US 2001-782433</u> A1 20010213 (9)	
PRAI <u>US 2000-182713P</u> 20000215 (60)	
DT Utility	
FS APPLICATION	
LN.CNT 1114	
INCL INCLM: 514/102.000	

INCLS: 514/091.000; 514/423.000; 514/460.000  
 NCL NCLM: 514/102.000  
 NCLS: 514/091.000; 514/423.000; 514/460.000  
 IC [7]  
 ICM: A61K031-675  
 ICS: A61K031-662; A61K031-366; A61K031-40  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 38 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:153016 USPATFULL  
 TI Prevention of loss and restoration of bone mass by certain prostaglandin agonists  
 IN Cameron, Kimberly O., East Lyme, CT, United States  
 Ke, Hua Z., Ledyard, CT, United States  
 Lefker, Bruce A., Gales Ferry, CT, United States  
 Rosati, Robert L., Mystic, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6288120 B1 20010911  
 WO 9828264 19980702  
 AI US 1999-331081 19990611 (9)  
 WO 1997-IB1417 19971110  
 19990611 PCT 371 date  
 19990611 PCT 102(e) date  
 PRAI US 1996-33451P 19961220 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 9116  
 INCL INCLM: 514/605.000  
 INCLS: 514/570.000; 564/099.000; 562/470.000  
 NCL NCLM: 514/605.000  
 NCLS: 514/570.000; 562/470.000; 564/099.000  
 IC [7]  
 ICM: A61K031-16  
 ICS: A61K031-19; C07C303-00; C07C059-48  
 EXF 562/470; 514/570; 514/605; 564/99  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 39 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:147980 USPATFULL  
 TI Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2  
 IN Ke, HuaZhu, Ledyard, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6284773 B1 20010904  
 AI US 1999-314371 19990714 (9)  
 PRAI US 1998-89468P 19980616 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 643  
 INCL INCLM: 514/317.000  
 INCLS: 514/573.000  
 NCL NCLM: 514/317.000  
 NCLS: 514/573.000  
 IC [7]

ICM: A61K031-445

ICS: A61K031-19; A61K031-557

EXF 514/317; 514/573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 40 OF 78 USPATFULL on STN

Full Text	References

AN 2001:145314 USPATFULL

TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

IN Maclean, David B., Providence, RI, United States

**Thompson, David D.**, Gales Ferry, CT, United StatesPI US 2001018451 A1 20010830US 6403611 B2 20020611AI US 2001-803516 A1 20010309 (9)RLI Continuation of Ser. No. US 1999-314758, filed on 19 May 1999, PENDING  
Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED,  
Pat. No. US 6107331PRAI US 1996-13212P 19960228 (60)

DT Utility

FS APPLICATION

LN.CNT 2063

INCL INCLM: 514/428.000

INCLS: 514/320.000; 514/304.000

NCL NCLM: 514/315.000

NCL NCLM: 514/428.000

NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000

IC [7]

ICM: A61K031-445

ICS: A61K031-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 41 OF 78 USPATFULL on STN

Full Text	References

AN 2001:131333 USPATFULL

TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

IN Maclean, David B., Providence, RI, United States

**Thompson, David D.**, Gales Ferry, CT, United States

PA Pfizer Inc, New York, NY, United States (U.S. corporation)

PI US 6274618 B1 20010814AI US 1999-314758 19990519 (9)RLI Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, now patented, Pat. No. US 6107331PRAI US 1996-13212P 19960228 (60)

DT Utility

FS GRANTED

LN.CNT 1933

INCL INCLM: 514/428.000

INCLS: 514/213.000; 514/317.000; 514/331.000

NCL NCLM: 514/428.000

NCLS: 514/317.000; 514/331.000

IC [7]

ICM: A61K031-40

ICS: A01N043-36

EXF 514/317; 514/213; 514/331; 514/428

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 42 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:119297 USPATFULL  
 TI Combination therapy for osteoporosis  
 IN Ke, Hua Zhu, Ledyard, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PI US 2001009920 A1 20010726  
 AI US 2000-736051 A1 20001213 (9)  
 RLI Division of Ser. No. US 1998-117972, filed on 11 Aug 1998, PENDING A 371  
 of International Ser. No. WO 1996-IB1462, filed on 23 Dec 1996, UNKNOWN  
 PRAI US 1996-12412P 19960228 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2509  
 INCL INCLM: 514/408.000  
 INCLS: 514/559.000  
 NCL NCLM: 514/408.000  
 NCLS: 514/559.000  
 IC [7]  
 ICM: A61K031-20  
 ICS: A01N037-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 43 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2000:137864 USPATFULL  
 TI Therapeutic combinations comprising a selective estrogen receptor  
 modulator and parathyroid hormone  
 IN Ke, HuaZhu, Ledyard, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6132774 20001017  
WO 9965482 19991223  
 AI US 1999-424010 19991115 (9)  
WO 1999-IB949 19990526  
 19991115 PCT 371 date  
 19991115 PCT 102(e) date

PRAI US 1998-89479P 19980616 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 650  
 INCL INCLM: 424/520.000  
 INCLS: 514/428.000  
 NCL NCLM: 424/520.000  
 NCLS: 514/428.000  
 IC [7]  
 ICM: A61K035-12  
 ICS: A61K031-40

EXF 514/428; 424/520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 44 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2000:109836 USPATFULL  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting  
 pathological conditions  
 IN MacLean, David B., Providence, RI, United States

**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6107331 20000822  
AI US 1997-803733 19970221 (8)  
PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1927  
 INCL INCLM: 514/428.000  
 INCLS: 514/427.000  
 NCL NCLM: 514/428.000  
 NCLS: 514/427.000  
 IC [7]  
 ICM: A61K031-40  
 EXF 514/427; 514/428  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 45 OF 78 USPATFULL on STN

Full Text	References
--------------	------------

AN 2000:102333 USPATFULL  
 TI Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists  
 IN Maclean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)  
PI US 6100301 20000808  
AI US 1998-92100 19980605 (9)  
PRAI US 1996-12409P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 743  
 INCL INCLM: 514/648.000  
 INCLS: 514/012.000  
 NCL NCLM: 514/648.000  
 NCLS: 514/012.000  
 IC [7]  
 ICM: A61K031-135  
 ICS: A61K038-00  
 EXF 514/648; 514/12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 46 OF 78 USPATFULL on STN

Full Text	References
--------------	------------

AN 2000:54092 USPATFULL  
 TI Combination therapy to prevent bone loss-progesterone and estrogen agonists  
 IN MacLean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6057309 20000502  
AI US 1998-193265 19981116 (9)  
RLI Continuation of Ser. No. US 1997-803710, filed on 21 Feb 1997, now abandoned  
PRAI US 1996-12400P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 438  
 INCL INCLM: 514/171.000

INCLS: 514/648.000  
 NCL NCLM: 514/171.000  
 NCLS: 514/648.000  
 IC [7]  
 ICM: A61K031-56  
 ICS: A61K031-135  
 EXF 514/648; 514/171  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 47 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2000:9953 USPATFULL  
 TI Method of increasing testosterone  
 IN MacLean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6017964 20000125  
 AI US 1998-208729 19981209 (9)  
 RLI Continuation of Ser. No. US 1997-803711, filed on 21 Feb 1997, now abandoned  
 PRAI US 1996-21181P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 348  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 48 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1999:146631 USPATFULL  
 TI Inhibition of autoimmune diseases  
 IN MacLean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)  
 PI US 5985932 19991116  
 AI US 1997-804346 19970221 (8)  
 PRAI US 1996-12402P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 392  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 49 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1999:90360 USPATFULL  
 TI Method and system for applying dispersive normal moveout corrections to seismic survey signals  
 IN Byun, Bok S., Plano, TX, United States

Thompson, David D., Plano, TX, United States  
 Nelan, E. Stuart, Dallas, TX, United States  
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S.  
 corporation)  
PI US 5933789 19990803  
AI US 1996-745452 19961112 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 998  
 INCL INCLM: 702/017.000  
 INCLS: 367/048.000; 367/052.000; 702/013.000  
 NCL NCLM: 702/017.000  
 NCLS: 367/048.000; 367/052.000; 702/013.000  
 IC [6]  
 ICM: G06F019-00  
 EXF 702/14; 702/17; 702/13; 367/48; 367/52

L2 ANSWER 50 OF 78 USPATFULL on STN

Full Text	Citing References
AN	1999:56502 USPATFULL
TI	Use of droloxifene for the treatment of cardiovascular disease
IN	Loser, Roland, Feldafing, Germany, Federal Republic of Schliack, Michael, Munich, Germany, Federal Republic of Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
<u>PI</u>	US 5902830 19990511
<u>AI</u>	US 1998-48568 19980326 (9)
<u>RLI</u>	Division of Ser. No. <u>US 1996-605131</u> , filed on 13 Mar 1996
DT	Utility
FS	Granted
LN.CNT	221
INCL	INCLM: 514/648.000
NCL	NCLM: 514/648.000
IC	[6] ICM: A61K031-135
EXF	514/648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 51 OF 78 USPATFULL on STN

Full Text	Citing References
AN	1999:40459 USPATFULL
TI	Method of treating diseases and conditions with estrogen agonists and antagonists
IN	MacLean, David B., Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
<u>PI</u>	US 5889042 19990330
<u>AI</u>	US 1997-803706 19970221 (8)
<u>PRAI</u>	US 1996-13213P 19960228 (60)
DT	Utility
FS	Granted
LN.CNT	1668
INCL	INCLM: 514/127.000
NCL	NCLM: 514/427.000
IC	[6] ICM: A61K031-40
EXF	514/427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 52 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1999:7425 USPATFULL  
 TI Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists  
 IN MacLean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5861438 19990119  
 AI US 1997-803712 19970221 (8)  
 PRAI US 1996-12399P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 530  
 INCL INCLM: 514/648.000  
 INCLS: 514/012.000  
 NCL NCLM: 514/648.000  
 NCLS: 514/012.000  
 IC [6]  
 ICM: A61K038-00  
 ICS: A61K031-135  
 EXF 514/12; 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 53 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:159989 USPATFULL  
 TI Use of droloxifene for the treatment of protastic disease, endometriosis and obesity  
 IN **Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5852059 19981222  
WO 9602243 19960201  
 AI US 1997-750860 19970106 (8)  
WO 1995-IB404 19950526  
 19970106 PCT 371 date  
 19970106 PCT 102(e) date  
 RLI Continuation-in-part of Ser. No. US 1994-276969, filed on 19 Jul 1994, now patented, Pat. No. US 5441986  
 DT Utility  
 FS Granted  
 LN.CNT 220  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 54 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:131754 USPATFULL  
 TI Use of droloxifene for the treatment of cardiovascular diseases  
 IN Loser, Roland, Feldafing, Germany, Federal Republic of  
 Schliack, Michael, Munchen, Germany, Federal Republic of  
**Thompson, David D.**, Gales Ferry, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5827892 19981027  
WO 9602242 19960201  
 AI US 1996-605131 19960313 (8)  
WO 1995-IB403 19950526  
 19960313 PCT 371 date  
 19960313 PCT 102(e) date  
 RLI Continuation-in-part of Ser. No. US 1994-276969, filed on 19 Jul 1994,  
 now patented, Pat. No. US 5441986  
 DT Utility  
 FS Granted  
 LN.CNT 224  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/651; 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 55 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 1998:75623 USPATFULL  
 TI Combination therapy to treat osteoporosis - polyphosphonates and  
 estrogen agonists  
 IN MacLean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5773477 19980630  
 AI US 1997-803707 19970221 (8)  
 PRAI US 1996-12409P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 499  
 INCL INCLM: 514/648.000  
 INCLS: 514/102.000; 514/108.000  
 NCL NCLM: 514/648.000  
 NCLS: 514/102.000; 514/108.000  
 IC [6]  
 ICM: A61K031-135  
 ICS: A61K031-66  
 EXF 514/648; 514/102; 514/108  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 56 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 1998:66277 USPATFULL  
 TI Method and system for surface-consistent phase and time lag correction  
 of seismic data  
 IN **Thompson, David D.**, Plano, TX, United States  
 Byun, Bok S., Plano, TX, United States  
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S.  
 corporation)  
 PI US 5764516 19980609  
 AI US 1995-580819 19951229 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1603  
 INCL INCLM: 364/421.000

INCLS: 367/054.000  
 NCL NCLM: 702/017.000  
 NCLS: 367/054.000  
 IC [6]  
 ICM: G06F019-00  
 EXF 364/421; 364/422; 367/48; 367/45; 367/50; 367/54; 367/38; 367/43;  
 367/47; 367/49; 367/72; 367/51

L2 ANSWER 57 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:33959 USPATFULL  
 TI Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder  
 IN MacLean, David B., Providence County, RI, United States  
 Thompson, David D., New London County, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5733937 19980331  
 AI US 1997-804702 19970221 (8)  
 PRAI US 1996-12410P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 363  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 58 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:25261 USPATFULL  
 TI Protection of ischemic myocardium against reperfusion damage  
 IN MacLean, David B., Groton, CT, United States  
 Thompson, David D., Groton, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5726207 19980310  
 AI US 1997-805040 19970221 (8)  
 PRAI US 1996-12401P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 303  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/646  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 59 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:17354 USPATFULL  
 TI 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease  
 IN Maclean, David B., Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5719191 19980217

AI US 1997-805039 19970221 (8)  
PRAI US 1996-25201P 19960228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 424  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 60 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:17353 USPATFULL  
 TI Inhibition of myeloperoxidase activity  
 IN MacLean, David B., Providence, RI, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 5719190 19980217  
AI US 1997-803709 19970221 (8)  
PRAI US 1986-12403P 19860228 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 362  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: A61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 61 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 96:120892 USPATFULL  
 TI Benzo-thiophene estrogen agonists to treat prostatic hyperplasia  
 IN Thompson, David D., Groton, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 5589482 19961231  
AI US 1994-356011 19941214 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 533  
 INCL INCLM: 514/305.000  
 INCLS: 324/212.000; 324/210.000; 324/422.000; 324/448.000  
 NCL NCLM: 514/305.000  
 NCLS: 324/210.000; 324/212.000; 324/422.000; 324/448.000  
 IC [6]  
 ICM: A61K031-44  
 ICS: A61K031-445; A61K031-395; A61K031-40  
 EXF 514/443; 514/324; 514/422; 514/578; 514/210; 514/448; 514/470; 514/418;  
 514/305; 514/212  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 62 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 95:73667 USPATFULL

TI Estrogen agonists as remedies for prostate and cardiovascular diseases  
 IN **Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 5441986 19950815  
 AI US 1994-276969 19940719 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 166  
 INCL INCLM: 514/648.000  
 NCL NCLM: 514/648.000  
 IC [6]  
 ICM: H61K031-135  
 EXF 514/648  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 63 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	92:84017	USPATFULL
TI	Mass retrieval for acoustic pulse generator	
IN	<b>Thompson, David D.</b> , Plano, TX, United States	
	Airhart, Tom P., Plano, TX, United States	
	Woodrow, Andrew B., Plano, TX, United States	
	Karner, Gary M., Garland, TX, United States	
PA	Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)	
PI	<u>US 5154254</u>	19921013
AI	<u>US 1990-510352</u>	19900416 (7)
DT	Utility	
FS	Granted	
LN.CNT	457	
INCL	INCLM: 181/121.000	
	INCLS: 181/114.000; 367/189.000	
NCL	NCLM: 181/121.000	
	NCLS: 181/114.000; 367/189.000	
IC	[5]	
	ICM: G01V001-04	
EXF	367/189; 367/190; 181/113; 181/114; 181/119; 181/121; 181/401	

L2 ANSWER 64 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	92:2056	USPATFULL
TI	3-dimensional migration of irregular grids of 2-dimensional seismic data	
IN	Mosher, Charles C., Plano, TX, United States	
	<b>Thompson, David D.</b> , Plano, TX, United States	
PA	Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)	
PI	<u>US 5079703</u>	19920107
AI	<u>US 1990-481868</u>	19900220 (7)
DT	Utility	
FS	Granted	
LN.CNT	451	
INCL	INCLM: 364/421.000	
	INCLS: 364/422.000; 367/051.000; 367/053.000; 367/072.000; 395/127.000	
NCL	NCLM: 702/016.000	
	NCLS: 345/427.000; 367/051.000; 367/053.000; 367/072.000	
IC	[5]	
	ICM: G01V001-00	
	ICS: G06F015-00	

EXF 367/53; 367/51; 367/72; 364/421; 364/521; 364/522

L2 ANSWER 65 OF 78 USPATFULL on STN

Full Text	CRING References
-----------	---------------------

AN 91:78304 USPATFULL  
 TI Method and apparatus for seismic survey including using vertical gradient estimation to separate downgoing seismic wavefield  
 IN Corrigan, Dennis, Plano, TX  
 Weglein, Arthur B., Grapevine, TX  
**Thompson, David D.**, Plano, TX  
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)  
 PI US 5051961 19910924  
 AI US 1989-427691 19891026 (7)  
 DT Utility  
 FS Granted  
 LN.CNT 670  
 INCL INCLM: 367/024.000  
 INCLS: 367/057.000  
 NCL NCLM: 367/024.000  
 NCLS: 367/057.000  
 IC [5]  
 ICM: G01V001-36  
 ICS: G01V001-38  
 EXF 367/21; 367/24; 367/23; 367/57; 367/59; 364/421; 364/422

L2 ANSWER 66 OF 78 USPATFULL on STN

Full Text	CRING References
-----------	---------------------

AN 82:2483 USPATFULL  
 TI Shoe tie stand  
 IN **Thompson, David D.**, Box 122, 410 N. Race St., Princeton, IN, United States 47670  
 PI US 262667 19820119  
 AI US 1980-129019 19800310 (6)  
 DT Design  
 FS Granted  
 LN.CNT 8  
 INCL INCLM: D03/030.500  
 INCLS: D06/085.000  
 NCL NCLM: D03/200.000  
 NCLS: D06/349.000; D06/410.000  
 IC [1]  
 ICM: D03-99  
 EXF D03/30.5; D06/85; 015/265; 211/34; 211/36; 211/37; 211/38

L2 ANSWER 67 OF 78 USPAT2 on STN

Full Text	CRING References
-----------	---------------------

AN 2003:312744 USPAT2  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions  
 IN MacLean, David B., Providence, RI, UNITED STATES  
**Thompson, David D.**, Gales Ferry, CT, UNITED STATES  
 PA Pfizer Inc, New York, NY, UNITED STATES (U.S. corporation)  
 PI US 6911456 B2 20050628  
 AI US 2002-133006 20020426 (10)  
 RLI Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, Pat. No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, Pat.

No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, Pat. No. US 6107331

PRAI US 1996-13212P 19960228 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2014  
 INCL INCLM: 514/315.000  
 INCLS: 514/428.000; 514/429.000  
 NCL NCLM: 514/315.000  
 NCL NCLM: 514/256.000  
 NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000;  
 514/314.000; 514/339.000; 514/394.000; 514/415.000  
 IC [7]  
 ICM: A61K031-445  
 EXF 514/315; 514/428; 514/429  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 68 OF 78 USPAT2 on STN

	Full Text	Citing References
AN	2003:232606	USPAT2
TI	Compositions and methods for treating osteoporosis and lowering cholesterol	
IN	Day, Wesley W., Old Lyme, CT, United States Lee, Andrew G., Old Lyme, CT, United States <b>Thompson, David D.</b> , Gales Ferry, CT, United States	
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)	
PI	<u>US 6756401</u>	B2 20040629
AI	<u>US 2001-767625</u>	20010123 (9)
PRAI	<u>US 2000-205327P</u>	20000421 (60)
	<u>US 2000-188923P</u>	20000126 (60)
DT	Utility	
FS	GRANTED	
LN.CNT	1547	
INCL	INCLM: 514/428.000 INCLS: 514/461.000; 514/473.000	
NCL	NCLM: 514/428.000	
NCL	NCLM: 514/307.000	
NCLS	514/461.000; 514/473.000; 514/319.000; 514/408.000; 514/412.000	
IC	[7] ICM: A61K031-40 ICS: A61K031-34	
EXF	514/317; 514/331; 514/428; 514/213; 514/423	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 69 OF 78 USPAT2 on STN

	Full Text	Citing References
AN	2003:153424	USPAT2
TI	Prevention of loss and restoration of bone mass by certain prostaglandin agonists	
IN	Cameron, Kimberly O., East Lyme, CT, United States Ke, Hua Z., Ledyard, CT, United States Lefker, Bruce A., Gales Ferry, CT, United States Rosati, Robert L., Mystic, CT, United States <b>Thompson, David D.</b> , Gales Ferry, CT, United States	
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)	
PI	<u>US 6649657</u>	B2 20031118
AI	<u>US 2002-256985</u>	20020926 (10)
RLI	Division of Ser. No. <u>US 2001-897824</u> , filed on 29 Jun 2001, now patented,	

Pat. No. US 6492412 Division of Ser. No. US 331081  
 PRAI WO 1997-1B1417 19971110  
 US 1996-33451P 19961220 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 8983  
 INCL INCLM: 514/545.000  
 INCLS: 514/570.000; 514/461.000; 514/438.000; 560/051.000; 562/459.000;  
 549/484.000; 549/070.000  
 NCL NCLM: 514/545.000  
 NCL NCLM: 514/227.500  
 NCLS: 514/438.000; 514/461.000; 514/570.000; 549/070.000; 549/484.000;  
 560/051.000; 562/459.000; 514/238.200; 514/252.100; 514/357.000;  
 514/365.000; 514/385.000; 514/399.000; 514/406.000; 514/602.000;  
 544/059.000; 544/159.000; 544/402.000; 546/334.000; 548/193.000;  
 548/235.000; 548/335.500; 564/095.000  
 IC [7]  
 ICM: A61K031-235  
 ICS: A61K031-34; C07C069-76; C07D307-02; C07D333-22  
 EXF 560/51; 514/545; 514/570; 514/461; 514/438; 562/459; 549/484; 549/70  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 70 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2002:280644 USPAT2  
 TI Methods and kits for improving vascular health  
 IN Day, Wesley W., San Diego, CA, United States  
 Lee, Andrew G., Old Lyme, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6620806 B2 20030916  
 AI US 2001-977458 20011015 (9)  
 PRAI US 2000-241532P 20001017 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2986  
 INCL INCLM: 514/217.030  
 INCLS: 514/212.000; 514/217.080; 514/315.000; 514/317.000; 514/323.000;  
 514/307.000; 514/345.000; 514/428.000; 514/213.000; 514/582.000;  
 514/585.000; 514/648.000; 514/331.000; 514/414.000; 514/415.000  
 NCL NCLM: 514/217.030  
 NCL NCLM: 514/266.200  
 NCLS: 514/211.150; 514/217.080; 514/218.000; 514/307.000; 514/315.000;  
 514/317.000; 514/323.000; 514/331.000; 514/345.000; 514/414.000;  
 514/415.000; 514/428.000; 514/582.000; 514/585.000; 514/648.000;  
 514/256.000; 514/266.210; 514/314.000; 514/337.000; 514/394.000  
 IC [7]  
 ICM: A61K031-55  
 EXF 514/428; 514/320; 514/305; 514/212; 514/323; 514/414; 514/415;  
 514/217.03; 514/217.08; 514/648; 514/317; 514/307; 514/315; 514/331;  
 514/345; 514/213; 514/482; 514/582; 514/585  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 71 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2002:172363 USPAT2  
 TI Use of estrogen antagonists and estrogen agonists in inhibiting  
 pathological conditions

IN Maclean, David B., Providence, RI, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6613796 B2 20030902  
AI US 2001-999291 20011115 (9)  
RLI Division of Ser. No. US 2000-511806, filed on 3 Feb 2000, now patented,  
Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb  
1997, now patented, Pat. No. US 6107331  
PRAI US 1996-13212P 19960228 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2003  
INCL INCLM: 514/428.000  
INCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000  
NCL NCLM: 514/428.000  
NCL NCLM: 514/217.010  
NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000;  
514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000  
IC [7]  
ICM: A61K031-40  
ICS: A61K031-445; A61K031-44  
EXF 514/428; 514/429; 514/343; 514/319; 514/315  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 72 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2002:73008 USPAT2  
TI EP4 receptor selective agonists in the treatment of osteoporosis  
IN Cameron, Kimberly O., East Lyme, CT, United States  
Ke, HuaZhu, Ledyard, CT, United States  
Lefker, Bruce A., Gales Ferry, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6642266 B2 20031104  
AI US 2001-991585 20011116 (9)  
RLI Division of Ser. No. US 2000-738670, filed on 15 Dec 2000  
PRAI US 1999-171353P 19991222 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1779  
INCL INCLM: 514/424.000  
INCLS: 514/381.000; 548/551.000  
NCL NCLM: 514/424.000  
NCL NCLM: 548/253.000  
NCLS: 514/381.000; 548/551.000; 548/550.000  
IC [7]  
ICM: A61K031-4015  
EXF 548/551; 548/253; 514/424; 514/381  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 73 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2002:27520 USPAT2  
TI Prevention of loss and restoration of bone mass by certain prostaglandin  
agonists  
IN Cameron, Kimberly O., East Lyme, CT, United States  
Ke, Hua Z., Ledyard, NY, United States  
Lefker, Bruce A., Gales Ferry, CT, United States

Rosati, Robert L., Mystic, CT, United States  
**Thompson, David D.**, Gales Ferry, CT, United States  
 PA Pfizer, Inc., New York, NY, United States (U.S. corporation)  
 PI US 6492412 B2 20021210  
 AI US 2001-897824 20010629 (9)  
 RLI Division of Ser. No. US 331081, now patented, Pat. No. US 6288120  
 PRAI US 1996-33451P 19961220 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 9168  
 INCL INCLM: 514/423.000  
 INCLS: 514/448.000; 514/570.000; 514/605.000; 548/531.000; 549/072.000;  
 564/099.000; 561/470.000  
 NCL NCLM: 514/423.000  
 NCL NCLM: 514/601.000  
 NCLS: 514/252.100; 514/255.050; 514/256.000; 514/448.000; 514/570.000;  
 514/605.000; 544/335.000; 544/336.000; 548/531.000; 549/072.000;  
 562/470.000; 564/099.000; 514/575.000; 514/626.000; 514/665.000;  
 562/623.000; 564/095.000; 564/193.000; 564/440.000  
 IC [7]  
 ICM: A61K031-40  
 ICS: A61K031-38; A61K031-19; C07D207-00; C07C303-00  
 EXF 514/605; 514/570; 514/448; 514/423; 564/99; 562/470; 549/72; 548/531  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 74 OF 78 USPAT2 on STN

Full Text	Cited References
AN	2001:218612 USPAT2
TI	EP4 receptor selective agonists in the treatment of osteoporosis
IN	Cameron, Kimberly O., East Lyme, CT, United States Ke, HuaZhu, Ledyard, CT, United States Lefker, Bruce A., Gales Ferry, CT, United States <b>Thompson, David D.</b> , Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	<u>US 6737437</u> B2 20040518
AI	<u>US 2000-738670</u> 20001215 (9)
PRAI	<u>US 1999-171353P</u> 19991222 (60)
DT	Utility
FS	GRANTED
LN.CNT	1797
INCL	INCLM: 514/424.000
NCL	NCLM: 514/424.000
NCL	NCLM: 560/001.000
	NCLS: 548/253.000; 548/551.000
IC	[7] ICM: A61K031-40
EXF	514/424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 75 OF 78 USPAT2 on STN

Full Text	Cited References
AN	2001:212438 USPAT2
TI	Methods of treatment for premature ejaculation in a male
IN	Lee, Andrew G., Old Lyme, CT, United States Day, Wesley W., Old Lyme, CT, United States <b>Thompson, David D.</b> , Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	<u>US 6512002</u> B2 20030128

AI US 2001-757423 20010110 (9)  
 PRAI US 2000-175704P 20000112 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1986  
 INCL INCLM: 514/427.000  
 INCLS: 514/415.000; 514/410.000; 514/429.000; 514/428.000  
 NCL NCLM: 514/427.000  
 NCL NCLM: 514/217.030  
 NCLS: 514/410.000; 514/415.000; 514/428.000; 514/429.000; 514/217.080;  
 514/317.000; 514/648.000  
 IC [7]  
 ICM: A61K031-40  
 ICS: A61K031-405  
 EXF 514/427; 514/428; 514/415; 514/410; 514/429  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 76 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2001:205936 USPAT2  
 TI Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure  
 IN Paralkar, Vishwas M., Madison, CT, United States  
 Thompson, David D., Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6610719 B2 20030826  
 AI US 2001-771164 20010129 (9)  
 PRAI US 2000-178968P 20000131 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 743  
 INCL INCLM: 514/381.000  
 INCLS: 514/352.000; 514/423.000; 514/573.000; 514/530.000  
 NCL NCLM: 514/381.000  
 NCL NCLM: 514/381.000  
 NCLS: 514/352.000; 514/423.000; 514/530.000; 514/573.000; 514/424.000  
 IC [7]  
 ICM: A61K031-41  
 ICS: A61K031-40  
 EXF 514/381; 514/382; 514/423  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 77 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2001:205925 USPAT2  
 TI Compositions and methods for treating conditions responsive to estrogen  
 IN Thompson, David D., Gales Ferry, CT, United States  
 Lee, Andrew G., Old Lyme, CT, United States  
 Day, Wesley W., Old Lyme, CT, United States  
 Rosati, Robert L., Stonington, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6632834 B2 20031014  
 AI US 2001-758778 20010111 (9)  
 PRAI US 2000-175752P 20000112 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1958  
 INCL INCLM: 514/428.000

NCL NCLM: 514/428.000  
 NCL NCLM: 514/317.000  
 NCLS: 514/308.000; 514/408.000  
 IC [7]  
 ICM: A61K031-40  
 EXF 514/428  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 78 OF 78 USPAT2 on STN

	Full Text	Citing References
AN	2001:145314	USPAT2
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions	
IN	Maclean, David B., Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States	
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)	
PI	US 6403611	B2 20020611
AI	US 2001-803516	20010309 (9)
RLI	Continuation of Ser. No. <u>US 1999-314758</u> , filed on 19 May 1999, now patented, Pat. No. <u>US 6274618</u> Continuation of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, now patented, Pat. No. <u>US 6107331</u>	
PRAI	US 1996-13212P	19960228 (60)
DT	Utility	
FS	GRANTED	
LN.CNT	2014	
INCL	INCLM: 514/315.000 INCLS: 514/428.000; 514/429.000	
NCL	NCLM: 514/315.000	
NCL	NCLM: 514/428.000 NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000	
IC	[7] ICM: A61K031-445	
EXF	514/429; 514/428; 514/315	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his full.

(FILE 'HOME' ENTERED AT 18:58:50 ON 10 AUG 2005)

FILE 'USPATFULL, USPAT2' ENTERED AT 18:59:06 ON 10 AUG 2005

E MACLEAN D/IN  
 L1 26 SEA "MACLEAN DAVID B"/IN  
 D 1-26  
 E THOMPSON D/IN  
 L2 78 SEA "THOMPSON DAVID D"/IN  
 D 1-78

FILE HOME

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Aug 2005 (20050809/PD)  
 FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)  
 HIGHEST GRANTED PATENT NUMBER: US6928656  
 HIGHEST APPLICATION PUBLICATION NUMBER: US2005172377  
 CA INDEXING IS CURRENT THROUGH 9 Aug 2005 (20050809/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Aug 2005 (20050809/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005

## USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

```

>>> USPAT2 is now available.  USPATFULL contains full text of the    <<<
>>> original, i.e., the earliest published granted patents or        <<<
>>> applications.  USPAT2 contains full text of the latest US        <<<
>>> publications, starting in 2001, for the inventions covered in    <<<
>>> USPATFULL.  A USPATFULL record contains not only the original    <<<
>>> published document but also a list of any subsequent             <<<
>>> publications.  The publication number, patent kind code, and     <<<
>>> publication date for all the US publications for an invention    <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.                                                         <<<

```

```

>>> USPATFULL and USPAT2 can be accessed and searched together      <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to        <<<
>>> enter this cluster.                                              <<<
>>>                                                                    <<<
>>> Use USPATALL when searching terms such as patent assignees,     <<<
>>> classifications, or claims, that may potentially change from    <<<
>>> the earliest to the latest publication.                          <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

## FILE USPAT2

```

FILE COVERS 2001 TO PUBLICATION DATE: 9 Aug 2005 (20050809/PD)
FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)
HIGHEST GRANTED PATENT NUMBER: US2004208056
HIGHEST APPLICATION PUBLICATION NUMBER: US2005172357
CA INDEXING IS CURRENT THROUGH 9 Aug 2005 (20050809/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Aug 2005 (20050809/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

```

USPAT2 is a companion file to USPATFULL. USPAT2 contains full text of the latest US publications, starting in 2001, for the inventions covered in USPATFULL. USPATFULL contains full text of the original published US patents from 1971 to date and the original applications from 2001. In addition, a USPATFULL record for an invention contains a complete list of publications that may be searched in standard search fields, e.g., /PN, /PK, etc.

USPATFULL and USPAT2 can be accessed and searched together through the new cluster USPATALL. Type FILE USPATALL to enter this cluster.

Use USPATALL when searching terms such as patent assignees, classifications, or claims, that may potentially change from the earliest to the latest publication.

=>